Latest news with #PredicTcell
Business Upturn
4 days ago
- Business
- Business Upturn
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) today announced that its artificial intelligence initiative, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model. Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model. This next phase of development builds on recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. 'We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,' said Mittul Mehta, Chief Information Officer and Head of 'Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701 [email protected]
Business Insider
15-07-2025
- Business
- Business Insider
AI Daily: OpenAI said to end acquisition talks with Windsurf
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly: Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. ACQUISITION TALKS: OpenAI has terminated discussions to acquire AI coding assistant maker Windsdurf over Microsoft (MSFT) IP concerns, The Information's Miles Kruppa and Natasha Mascarenhas report. Instead, Google (GOOGL) intends to hire Windsurf's CEO and some staff, the authors note. RESEARCHERS: Meta (META) has brought in two more AI researchers from Microsoft-backed (MSFT) OpenAI as CEO Mark Zuckerberg continues aggressive efforts to recruit talent in the space, The Information's Kalley Huang reports. Allan Jabri and Lu Liu, who worked on multimodal AI at the ChatGPT maker, are joining Meta Superintelligence Labs, the author says, citing a person with direct knowledge of the hires. DATA CENTER: Meta CEO Mark Zuckerberg said on Threads that the company is building out a data center, Hyperion, which should supply Meta's new AI lab with 5GW of computational power. 'We're actually building several multi-GW clusters. We're calling the first one Prometheus and it's coming online in '26. We're also building Hyperion, which will be able to scale up to 5GW over several years. We're building multiple more titan clusters as well. Just one of these covers a significant part of the footprint of Manhattan… Meta Superintelligence Labs will have industry-leading levels of compute and by far the greatest compute per researcher. I'm looking forward to working with the top researchers to advance the frontier!' PLAYAI: Meta has completed a deal to acquire PlayAI, an AI startup focused on voice tech, Kurt Wagner of Bloomberg reports. The 'entire PlayAI team' is set to join Meta next week, Bloomberg notes, citing an internal memo. ALPHA VERSION: (TVGN), in collaboration with Microsoft (MSFT) and Databricks, has built the alpha version of its foundational PredicTcell model. PredicTcell is powered by a robust and scalable data engineering pipeline. Utilizing machine learning and transformer architectures trained on a terabyte-scale dataset encompassing nearly a billion genetic and proteomic elements, the model enhances target discovery. Through parallel processing and distributed computing, dramatically reduces protein sequence analysis and peptide identification from months to hours.
Yahoo
10-06-2025
- Business
- Yahoo
Tevogen expands headquarters in Warren, New Jersey
Tevogen (TVGN) announced the execution of a lease agreement to expand its corporate headquarters in Warren, New Jersey, more than doubling its footprint. The expanded space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development, thereby increasing operational efficiency and enhancing cross-team collaboration. The headquarters will also house and the Generics & Biosimilars initiative, with dedicated facilities for growing team of data scientists and engineers as development of its proprietary AdapTcell and PredicTcell algorithms accelerates. In addition to these core initiatives, the expanded facility could provide capacity to support potential new business units as Tevogen continues to grow and diversify its portfolio. The newly leased space was formerly occupied by CAPTRUST, a national investment advisory firm with reported total client assets exceeding $1 trillion. Tevogen is proud to continue building in this high-profile location and expresses its sincere appreciation to the building's owner, Mitsui Sumitomo Insurance Company of America, and parent company MS&AD Insurance Group Holdings Inc., for their continued support. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on TVGN: Disclaimer & DisclosureReport an Issue Tevogen Bio Expands Office Space in New Jersey AI Daily: OpenAI argues to keep countersuit against Musk Tevogen details AI initiative, with Microsoft, Databricks pacts Tevogen announces planned expansion of TVGN 489's target population Tevogen CEO says business model addresses biopharma industry challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs. currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for team of data scientists and engineers. Tevogen CEO, Dr. Ryan Saadi, commented, 'Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare.' Strategic Partnerships: Microsoft (Nasdaq: ): Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes. Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen's AI models and enhance predictive accuracy. Proprietary Technology: PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments. The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio's pipeline. To date, has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome. AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells. AdapTcell is expected to significantly enhance Tevogen Bio's understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map. plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results. Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@ in to access your portfolio
Yahoo
01-05-2025
- Business
- Yahoo
Tevogen sees launch year oncology business revenue $1B
Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative five-year estimate of between $10B and $14B. The forecast reflects the company's drug development model. 'With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,' commented Ryan Saadi, founder and CEO of Tevogen. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on TVGN: Disclaimer & DisclosureReport an Issue Tevogen Bio Signs Agreement with CD 8 Technology Tevogen says Databricks commissioned to accelerate PredicTcell development Tevogen announces Tevogen Generics following Trump's tariff-related statements Tevogen Bio Holdings Delays Annual Report Filing Tevogen announces new patent filed for T cell vaccine Sign in to access your portfolio
